Publication:
Oxidized Low-Density Lipoprotein Receptor in Lymphocytes Prevents Atherosclerosis and Predicts Subclinical Disease

dc.contributor.authorTsilingiri, Katerina
dc.contributor.authorde la Fuente, Hortensia
dc.contributor.authorRelano, Marta
dc.contributor.authorSanchez-Diaz, Raquel
dc.contributor.authorRodriguez, Cristina
dc.contributor.authorCrespo, Javier
dc.contributor.authorSanchez-Cabo, Fatima
dc.contributor.authorDopazo, Ana
dc.contributor.authorAlonso-Lebrero, José L
dc.contributor.authorVara, Alicia
dc.contributor.authorVazquez, Jesus
dc.contributor.authorCasasnovas, José M
dc.contributor.authorAlfonso, Fernando
dc.contributor.authorIbáñez, Borja
dc.contributor.authorFuster, Valentin
dc.contributor.authorMartinez-Gonzalez, Jose
dc.contributor.authorMartin, Pilar
dc.contributor.authorSanchez-Madrid, Francisco
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderCentro de Investigación Biomedica en Red - CIBER
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC)
dc.contributor.funderUnión Europea. Comisión Europea
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderFundación ProCNIC
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.contributor.funderBanco Santander
dc.date.accessioned2019-01-28T15:02:30Z
dc.date.available2019-01-28T15:02:30Z
dc.date.issued2019-01-08
dc.description.abstractBACKGROUND: Although the role of Th17 and regulatory T cells in the progression of atherosclerosis has been highlighted in recent years, their molecular mediators remain elusive. We aimed to evaluate the association between the CD69 receptor, a regulator of Th17/regulatory T cell immunity, and atherosclerosis development in animal models and in patients with subclinical disease. METHODS: Low-density lipoprotein receptor-deficient chimeric mice expressing or not expressing CD69 on either myeloid or lymphoid cells were subjected to a high fat diet. In vitro functional assays with human T cells were performed to decipher the mechanism of the observed phenotypes. Expression of CD69 and NR4A nuclear receptors was evaluated by reverse transcription-polymerase chain reaction in 305 male participants of the PESA study (Progression of Early Subclinical Atherosclerosis) with extensive (n=128) or focal (n=55) subclinical atherosclerosis and without disease (n=122). RESULTS: After a high fat diet, mice lacking CD69 on lymphoid cells developed large atheroma plaque along with an increased Th17/regulatory T cell ratio in blood. Oxidized low-density lipoprotein was shown to bind specifically and functionally to CD69 on human T lymphocytes, inhibiting the development of Th17 cells through the activation of NR4A nuclear receptors. Participants of the PESA study with evidence of subclinical atherosclerosis displayed a significant CD69 and NR4A1 mRNA downregulation in peripheral blood leukocytes compared with participants without disease. The expression of CD69 remained associated with the risk of subclinical atherosclerosis in an adjusted multivariable logistic regression model (odds ratio, 0.62; 95% CI, 0.40-0.94; P=0.006) after adjustment for traditional risk factors, the expression of NR4A1, the level of oxidized low-density lipoprotein, and the counts of different leucocyte subsets. CONCLUSIONS: CD69 depletion from the lymphoid compartment promotes a Th17/regulatory T cell imbalance and exacerbates the development of atherosclerosis. CD69 binding to oxidized low-density lipoprotein on T cells induces the expression of anti-inflammatory transcription factors. Data from a cohort of the PESA study with subclinical atherosclerosis indicate that CD69 expression in PBLs inversely correlates with the presence of disease. The expression of CD69 remained an independent predictor of subclinical atherosclerosis after adjustment for traditional risk factors.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipFunding was provided by the Spanish Ministry of Economy and Competitiveness: Plan Nacional de Salud SAF2017-82886-R to Dr Sánchez-Madrid, SAF2015-64767-R to Dr Martínez-González; Instituto de Salud Carlos III (AES 2016): PI16/01956 to Dr Martin, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares; European Research Council, ERC-2011-AdG294340-GENTRIS to Dr Sánchez-Madrid; Proyecto Integrado de Excelencia PIE13/041 and Fundació La Marató TV3 (20152330 31); and Comunidad Autónoma de Madrid CAM (S2017/BMD-3671) to Drs Martin and Sánchez-Madrid. Dr Tsilingiri is cofunded by the European Union Marie Curie Program. M. Relaño is supported by a Contratos Predoctorales Severo Ochoa para la formación de doctores (BES-2015–072625) from the Spanish Ministry of Economy and Competitiveness. This research has been cofinanced by Fondo Europeo de Desarrollo Regional. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, is supported by the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). The PESA study is cofunded equally by the Pro CNIC Foundation and Banco Santander, Madrid, Spain.es_ES
dc.format.number2es_ES
dc.format.page243-255es_ES
dc.format.volume139es_ES
dc.identifier.citationCirculation. 2019; 139(2):243-255es_ES
dc.identifier.doi10.1161/CIRCULATIONAHA.118.034326es_ES
dc.identifier.e-issn1524-4539es_ES
dc.identifier.issn0009-7322es_ES
dc.identifier.journalCirculationes_ES
dc.identifier.pubmedID30586697es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7016
dc.language.isoenges_ES
dc.publisherAmerican Heart Association (AHA)es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017-82886-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-64767-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01956es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/294340/EUes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BES-2015–072625es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Comunicación Intercelular en la Respuesta Inflamatoriaes_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Bioinformáticaes_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Genómicaes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovasculares_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionaleses_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Moléculas Reguladoras de los Procesos Inflamatorioses_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCD69 antigenes_ES
dc.subjectTh17 cellses_ES
dc.subjectAtherosclerosises_ES
dc.subjectOxidized low density lipoproteines_ES
dc.subjectRegulatory T lymphocyteses_ES
dc.titleOxidized Low-Density Lipoprotein Receptor in Lymphocytes Prevents Atherosclerosis and Predicts Subclinical Diseasees_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication360f4ceb-84d7-4b15-8a02-cc53fd49784d
relation.isAuthorOfPublication6133db00-3a6a-45fc-b6b0-4e058260c02f
relation.isAuthorOfPublication9b041652-76a7-4207-9438-00515f876967
relation.isAuthorOfPublicationdf49daaf-d2e0-4b73-b943-0ea2461280e3
relation.isAuthorOfPublicationecd7f1e7-2399-4c06-bbc6-d1a2e86c0fbe
relation.isAuthorOfPublication90c95c5b-73c0-44ee-8f23-a0d92a30c789
relation.isAuthorOfPublication9743763b-919c-4fa9-a53c-57c41be5e0ac
relation.isAuthorOfPublication2cac8bb6-2bff-4bf6-8209-bdbd21781786
relation.isAuthorOfPublication558474d4-85be-4127-bda8-59128f707249
relation.isAuthorOfPublication0d59911b-a54f-4013-9132-599072d32bdc
relation.isAuthorOfPublication51eb6cbc-309f-4845-987e-5b2cea239c59
relation.isAuthorOfPublication.latestForDiscovery360f4ceb-84d7-4b15-8a02-cc53fd49784d

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
OxidizedLowDensityLipoprotein_2019.pdf
Size:
1.89 MB
Format:
Adobe Portable Document Format
Description:
Loading...
Thumbnail Image
Name:
OxidizedLowDensityLipoprotein_2019_supp1.pdf
Size:
8.31 MB
Format:
Adobe Portable Document Format
Description: